Lv41
560 积分 2024-11-19 加入
Oral PCSK9 Inhibitors: Will They Work?
6小时前
已完结
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
26天前
已完结
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
27天前
已完结
Small molecules as inhibitors of PCSK9: Current status and future challenges
27天前
已完结
Molecular biology of PCSK9: its role in LDL metabolism
27天前
已完结
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
28天前
已完结
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
1个月前
已完结
Engineering the next generation of cell-based therapeutics
1个月前
已完结
[Influencing Factors of FeCl
1个月前
已关闭
Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab
1个月前
已完结
皖公网安备34019202002308
